The purpose of this study was to compare the efficacy of a 14-day course of
prulifloxacin 600 mg with standard
antibiotic therapy for the treatment of chronic
prostatitis due to Chlamydia trachomatis (Ct)
infection. All patients with clinical and instrumental diagnosis of bacterial chronic
prostatitis (CP) due to Ct
infection were enrolled. After randomization, all patients were administered oral
prulifloxacin 600 mg once daily for 14 days or
doxycycline 100 mg orally twice daily for 21 days. At enrollment and 30 days after beginning treatment, all patients underwent microbiological cultures for uropathogens bacteria and yeasts,
DNA extraction and mucosal
IgA evaluation for Ct diagnosis, seminal plasma
IL-8 evaluation and serum
IgA and
IgG anti-Ct analysis. The National Institutes of Health - Chronic
Prostatitis Symptom Index (NIH-CPSI) was given to each patient. A total of 109 patients received
prulifloxacin and 102 received standard
therapy.
Prulifloxacin had clinical efficacy rates equivalent to standard
therapy (82.5% vs. 79.9%) (P = 0.08) and showed superior microbiological efficacy rates compared to standard
therapy, in terms of decreasing mucosal
IgA (P < 0.001) and
IL-8 levels (P < 0.001).
Prulifloxacin was also equivalent to standard
therapy for clinical success, as demonstrated by a decrease in the number of patients affected by CP due to Ct
infection.